Litigation

Recent Posts

Johnson & Johnson Reserves $600M To Settle Risperdal, Invega, Natrecor Civil Cases
Posted on 11 Jun 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) Johnson & Johnson (J&J) expects to incur a special charge against earnings of about $600 million in the second quarter for the potential settlement of civil litigation related to Risperdal, Invega, Natrecor... Read More

Tags: SEC civil cases , Risperdal , Johnson , Natrecor , Invega , amp , Johnson &amp

Scios To Plead Guilty, Pay $85 Million For Off-Label Marketing Of Natrecor
Posted on 15 Sep 2011 by Tom Moylan

SAN FRANCISCO -- The Scios Inc. subsidiary of Johnson & Johnson has agreed to plead guilty to a misdemeanor charge related to the off-label marketing of its Natrecor heart drug, to pay an $85 million fine and to serve three years' organizational... Read More

Tags: False Claims Act , heart drug , off-label marketing , United States of America v. Scios , Johnson , Natrecor , Food Drug and Cosmetic Act , Scios , Litigation , Johnson &amp

Johnson & Johnson, 2 Units Plead Guilty, Pay $2.2 Billion In Criminal, Civil Penalties
Posted on 4 Nov 2013 by Tom Moylan

WASHINGTON, D.C. — (Mealey’s) Two Johnson & Johnson subsidiaries have pleaded guilty, and the parent company and two subsidiaries will pay $2.2 billion in criminal fines, civil penalties and forfeitures in one criminal and several civil... Read More

Tags: drugs , Medicare , off-label marketing , Risperdal , Natrecor , Medicaid , Litigation , Invega , United States of America v. Janssen Pharmaceuticals , Janssen Pharmaceuticals Inc. , Scios Inc. , diabetes , Johnson & Johnson , antipsychotic drug , U.S. Justice Department